IMI2



Big Data for Better Outcomes (BD4BO) Programme

Experience of a big data project from a Hungarian partner

László Bencze | legal expert, project coordinator | Semmelweis University – Health Services Management Training Centre

31 January 2019







Evolution of Big Data in IMI

Improve health outcomes and healthcare systems in Europe by maximising the potential of Big Data







Mission: Improve health outcomes and healthcare systems in Europe by maximising the potential of Big Data



THEMES/ENABLERS:

| Design sets of standard outcomes and demonstrate value | Increase access to high quality outcomes data | Use data to improve value of HC delivery | Increase patient engagement through digital solutions | |
|--------------------------------------------------------------|-----------------------------------------------|---------------------------------------------|-------------------------------------------------------|--|
| DISEASE-SPECIFIC PROJECTS: | | | | |
| ROADMAP: Alzheimer's disea | se | | | |
| HARMONY: Haematologic ma | lignancies | | | |
| BigData@Heart: Cardiovascul | ar diseases | | | |
| PIONEER: Prostate cancer | | | | |
| More to come | | | | |
| CO-ORDINATING PROJECTS: | | | | |
| | European Health Data and Evide | ence Network (EHDEN) | | |
| DO->IT: Coordination & support actions | | | | |

BD4BO Overview

DO->IT The overarching coordination structure for all BD4BO projects



| Type of project | Expected outputs | Timeline |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Coordination and support action | Develop and coordinate the overall BD4BO programme strategy Identify best practice for standardisation, selection and measurement of outcomes, data management Build an online repository to share knowledge and learning across the BD4BO programme Lead communication activities of the BD4BO programme Facilitate stakeholder engagement Develop minimum data privacy standards for ICFs, explanatory information and training material | 2017 – 2019 |


Coordinating Project

www.bd4bo.eu





Improve health outcomes and healthcare systems in Europe by maximising the potential of Big Data



BD4BO Expected Impact



Challenges (external and internal):



- Clarify mission and objectives
 - Ensure patient perspective
 - Address data privacy
 - Align different approaches

Responses:

- Clear communication
- Stakeholder engagement
- Involvement of ethics committees
 - Building trust

Challenges and Responses







Benefits for Society

Coordinating Partner: London School of Economics and Political Science Industry Lead: Novartis

PUBLIC PARTNERS

National Institute for Health and Care Excellence Dental and Pharmaceutical Benefits Agency European Cancer Patient Coalition European Multiple Sclerosis Platform Semmelweis University Imperial College London Swedish Institute for Health Economics Centre for Research in Healthcare Management – Università Bocconi Norwegian Institute of Public Health University of Liverpool Norwegian Medicines Agency Technology, Methods and Infrastructure for Networked Medical Research Inserm Toulouse

PRIVATE PARTNERS The Association of the British Pharmaceutical Industry Amgen

DO->IT Partners

Bayer **Boehringer Ingelheim** Celgene European Federation of Pharmaceutical Industries and Associations Farmaindustria GlaxoSmithKline Health iO Intersystems Janssen Pharmaceutica NV Eli Lilly and Company Merck MSD Novo Nordisk Pfizer Roche Sanofi Servier UCB Association of Research-Based Pharmaceutical Companies

BD4B0



Thank you!

€ bd4bo.eu ♥ @bd4bo



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) under grant agreement No. 116055. This Joint Undertaking receives support from the European Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).